©2022 Stanford Medicine
Group Therapy for Primary Breast Cancer
Trial ID: NCT00220792
The purpose of this study is to determine whether women with primary breast cancer who were randomly assigned to receive a brief group therapy would show a greater reduction in mood disturbance over time compared to those randomized to the control condition. We also hypothesized that women who were highly distressed at baseline would show the greatest benefit from participating in a support group, and that therapists with more training and experience would be most effective in reducing distress.
A Multicenter Trial of Group Therapy for Breast Cancer
- : 1) diagnosis of primary, biopsy-proven breast cancer, stages I through IIIA; 2)
diagnosis occurred no more than 12 months prior to recruitment; 3) completion of
initial surgical treatment; and 4) no detectable disease present.
- 1) evidence of metastases beyond adjacent lymph nodes, including chest wall
involvement, bone or viscera; 2) recurrence of the cancer prior to randomization; 3)
diagnosis of other cancers (except for basal cell or squamous cell carcinoma of the
skin or in situ cervical cancer) within the past 10 years; 4) any other major medical
problems likely to limit life expectancy to less than 10 years; 5) a history of major
psychiatric illness for which the patient was hospitalized or medicated, except for a
diagnosis of depression or anxiety treated for a period of less than one year; and 6)
attendance at a cancer support group for more than two months.
behavioral: Brief supportive-expressive group therapy
School of Medicine
300 Pasteur Drive
Stanford, CA 94305